Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
741 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.83 - $94.75
Previous Close$41.31
Volume866.63K
Average Volume (3M)1.45M
Market Cap
$5.01B
Enterprise Value$4.80B
Total Cash (Recent Filing)$325.90M
Total Debt (Recent Filing)$109.14M
Price to Earnings (P/E)-11.9
Beta0.42
Next Earnings
Aug 05, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding121,365,555
10 Day Avg. Volume1,727,099
30 Day Avg. Volume1,451,533
Standard Deviation0.21
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)19.11
Price to Sales (P/S)29.09
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.25
Enterprise Value/Gross Profit12.29
Enterprise Value/Ebitda-12.43
Forecast
1Y Price Target
$77.73Price Target Upside88.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityThe announcement of a new credit facility that extends the maturity date to 2030 represents an improvement in the company's financial flexibility, allowing for more strategic growth opportunities.
Market Share And DemandWith a market share of approximately 85% for Syfovre in treating GA patients, the company demonstrates a dominant position in the market, reflecting strong demand and competitive strength.
Product Performance And GrowthSyfovre's consistent revenue growth and the expansion to over 2,000 sites highlight the product's strong market acceptance and the company's robust growth trajectory.
Bears Say
Competitive Market DynamicsIncreased competition is expected to make revenue beats more challenging for Syfovre, which doesn't bode well for the stock's outlook.
Drug Safety ConcernsThe increase in reported serious adverse events for Syfovre is 39%, significantly impacting the drug's safety perception.
Regulatory ChallengesApellis Pharmaceuticals is facing a re-review of pegcetacoplan for GA due to potential conflicts of interest in the original expert group, which could negatively impact approval prospects.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $94.75 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 05, 2024 which is in 79 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.063.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.28.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 121,365,555 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -10.059%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Driehaus Capital Management LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 29M.
---
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.73 (88.16% Upside)
$77.73 (88.16% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.71%
12-Months-Change
Fundamentals
Return on Equity
-122.94%
Trailing 12-Months
Asset Growth
-15.01%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q1 2024
0:00 / 0:00
---
APLS Stock 12 Month Forecast
Average Price Target
$77.73
▲(88.16% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Ultragenyx Pharmaceutical
―
Karyopharm Therapeutics
―
Best Analysts Covering APLS
1 Year
1 Year Success Rate
15/24 ratings generated profit
1 Year Average Return
+15.01%
reiterated a buy rating 6 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +15.01% per trade.
---